drugset / Trial / NCT03594435
Ibudilast for the Treatment of Alcohol Use Disorder
Phase 2
Completed
102 enrolled
University of California, Los Angeles
MediciNova · collabNational Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2023-04-19
- Completion
- 2023-04-19
Publications
- McManus KR, Enders C, Kirsch DE, Belnap M, Grodin EN, Ray LA. Peripheral inflammation mediates the relationship between early life stress and alcohol use. Psychopharmacology (Berl). 2026 Jan 28:10.1007/s00213-026-07009-8. doi: 10.1007/s00213-026-07009-8. Online ahead of print.
- Ray LA, Meredith LR, Grodin EN, Belnap MA, Nieto SJ, Baskerville WA, Donato S, Shoptaw SJ, Gillis AJ, Irwin MR, Miotto K, Enders CK. A Neuroimmune Modulator for Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 Apr 1;8(4):e257523. doi: 10.1001/jamanetworkopen.2025.7523.
- Burnette EM, Baskerville WA, Grodin EN, Ray LA. Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial. Trials. 2020 Sep 11;21(1):779. doi: 10.1186/s13063-020-04670-y.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibudilast | Small molecule | 50 mg | — |